Transverse Myelitis (TM) Program

What we do

As one of only two dedicated transverse myelitis programs in the world, we have served as an epicenter of research, discovery, and highly specialized patient care since 2009. Along with seeing patients in our clinic – from 47 states and 10 countries to date – we regularly consult with clinicians around the world to expand the reach of advanced TM care. The TM team has been investigating the immune profiles of patients with myelitis who were diagnosed with MS in comparison to other conditions. We also collaborate closely with the Siegel Rare Neuroimmune Association (SRNA) to assist individuals with TM and their families in staying informed about the latest treatments and research developments.